Quick Takeaways
- Fortress Biotech, Inc. filed SCHEDULE 13D/A for Avenue Therapeutics, Inc. Common Stock, $0.0001 Par Value (ATXI).
- Disclosed ownership: 10%.
- Date of event: 31 Mar 2025.
Fortress Biotech, Inc. - 31 Mar 2025 SCHEDULE 13D/A Report for Avenue Therapeutics, Inc. Common Stock, $0.0001 Par Value (ATXI)
- Filing Manager
- Fortress Biotech, Inc.
- Reporting Manager
- Fortress Biotech, Inc.
- Symbol
- ATXI
- Shares outstanding
- 3,191,709 shares
- Disclosed Ownership
- 328,746 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13D/A
- Filing time
- 02 Apr 2025, 17:00:06 UTC
- Date of event
- 31 Mar 2025
- Previous filing
- 03 Jan 2025
- Next filing
- 06 Jan 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Fortress Biotech, Inc. disclosed 10% ownership in Avenue Therapeutics, Inc. Common Stock, $0.0001 Par Value (ATXI) on 31 Mar 2025."
What Changed
- Previous schedule filing date: 03 Jan 2025.
- Current filing was accepted on 02 Apr 2025, 17:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Fortress Biotech, Inc. | 10% | 328,746 | 328,746 | 0 | /s/ Lindsay A. Rosenwald | Lindsay A. Rosenwald, M.D. / Chairman, President and Chief Executive Officer | 0001429260 |